Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?

Beta-blocker therapy had benefits for survival in stable heart-failure patients. Results should not, however, be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.